{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for finerenone in Code Literal (approximate match)
Showing 1 - 1 of 1 results
Status:
US Approved Rx
(2021)
Source:
NDA215341
(2021)
Source URL:
First approved in 2021
Source:
NDA215341
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
FINERENONE is a potent and selective nonsteroidal mineralocorticoid receptor antagonist. Results in preclinical studies showed that lower doses of FINERENONE were needed to achieve similar cardiorenal protective effects compared to both spironolactone and eplerenone. It is in phase III clinical trials for the treatment of diabetic kidney disease.
